Clinical trials: Infection, COVID-19
COVID-19, COVID-19 Drug Treatment
Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial
In January 2020, the new SARS-CoV-2 coronavirus was identified in China. The disease caused by this coronavirus was named COVID-19 by the World Health Organization (WHO).
- Conditions
- COVID-19, COVID-19 Drug Treatment, Severe Acute Respiratory Syndrome Coronavirus 2
- Trial name
- INTENSE-COV (NCT04466241)
- Testing
- Lopinavir/Ritonavir 200 MG-50 MG Oral Tablet, Telmisartan 40Mg Oral Tablet, Atorvastatin 20 Mg Oral Tablet
- Where
- 2 sites in Côte d’Ivoire
- Volunteers
- 294 people
- Sponsor
- ANRS, Emerging Infectious Diseases
COVID-19, Thermotherapy
Local Thermotherapy for Patients With Mild-to-moderate COVID-19
The etiological agent of the current pandemic is a (+)ssRNA virus. SARS-CoV-2 is infecting thousands of people in the world with a fatality rate that varies from 0.1 to 5% in affected countries, thereby causing enormous economic…
- Trial name
- TherMoCoV (NCT04363541)
- Testing
- Electric pad for human external pain therapy
- Where
- 3 sites in Mexico
- Volunteers
- 274 people
- Sponsor
- Instituto Nacional de Perinatologia
COVID-19, Cancer
Impact of the COVID-19 Infectious Epidemic on the Management of Oncology and Onco-hematology Patients and on the Psychological Consequences for Patients and Caregivers
This original study will assess the impact of the coronavirus health crisis on the management of patients undergoing medical treatment for cancer, in particularly on the modification of the hospital organization.
- Trial name
- COVIPACT (NCT04366154)
- Testing
- Questionnaire
- Where
- 2 sites in France
- Volunteers
- 809 people, healthy volunteers welcome
- Sponsor
- Centre Francois Baclesse
COVID-19
Lung Injury (Pulmonary Edema) in COVID-19: Treatment With Furosemide and Negative Fluid Balance (NEGBAL)
In COVID-19, pulmonary edema has been attributed to "cytokine storm". However, it is known that SARS-CoV-2 promotes angiotensin-converting enzyme 2 deficiency, it increases angiotensin II and this triggers volume overload.
- Trial name
- NCT05304702
- Where
- Argentina
- Volunteers
- 120 people
- Sponsor
- Clinica Colon
COVID-19
Study of Remdesivir in Participants Below 18 Years Old With COVID-19
The goals of this clinical study are to learn more about the study drug, remdesivir, and how safe it is in participants less than 18 years old with coronavirus disease 2019 (COVID-19).
- Trial name
- CARAVAN (NCT04431453)
- Testing
- Remdesivir
- Where
- 32 sites in United States, Italy and 2 more
- Volunteers
- 59 people
- Sponsor
- Gilead Sciences
Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)
Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)
The objectives of this intermediate-size expanded access protocol are to assess the safety and efficacy of remestemcel-L in participants with MIS-C associated with COVID-19.
- Trial name
- NCT04456439
- Testing
- Remestemcel-L, Hydrocortisone, Diphenhydramine
- Sponsor
- Mesoblast International Sàrl
Covid19, Pneumonia
Coronavirus: Ventilator Outcomes Using Artificial Intelligence Chest Radiographs & Other Evidence-based Co-variates
We will determine ventilator outcomes to Coronavirus Infectious Disease 2019 (COVID-19) using artificial Intelligence with inputs of chest radiographs and other evidence-based co-variates.
- Trial name
- COVID VOICE (NCT04855539)
- Where
- 3 sites in United Kingdom
- Volunteers
- 300 people
- Sponsor
- King's College Hospital NHS Trust
SARS-CoV-2, COVID-19
Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data
This study aims to use vaccination information from state vaccine registries linked with HealthVerity insurance claims for the following: to measure how effective the Pfizer-BioNTech vaccine is at preventing post-COVID…
- Conditions
- SARS-CoV-2, COVID-19, Post-Acute COVID-19 Syndrome
- Trial name
- NCT05876377
- Testing
- Pfizer-BioNTech COVID-19 mRNA vaccine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Pfizer
COVID-19 Infection, Malignant Solid Neoplasm
Impact of the COVID-19 Pandemic and HRQOL in Cancer Patients and Survivors
This study uses questionnaires to gain an understanding of how experiences during the COVID-19 pandemic, regardless of COVID-19 status, may have impacted health-related quality of life (HRQOL) and other areas such as…
- Trial name
- NCT04447222
- Testing
- Quality-of-Life Assessment, Questionnaire Administration, Survey Administration
- Where
- United States
- Volunteers
- 1,242 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Covid19
Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled APN01 Developed as Treatment for COVID-19
APN01 is a soluble recombinant form of the human angiotensin-converting enzyme 2 (rhACE2) that is currently under development as a therapy for corona-virus-disease 2019 (COVID-19).
- Trial name
- NCT05065645
- Testing
- Angiotensin Converting Enzyme 2, Sodium chloride
- Where
- Austria
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Apeiron Biologics
Covid19
Study Evaluating the Olfactory Recovery of Anosmia Post COVID-19 by Olfactory Rehabilitation Assisted by Web-application
Anosmia is a symptom present in 40 to 80% of patients and usually only lasts 1 to 2 weeks. However, in nearly one in five patients, it can last beyond or even several months with consequences in terms of undernutrition and…
- Trial name
- COVIDANOSMIA (NCT04806880)
- Testing
- Web-application
- Where
- France
- Volunteers
- 1,155 people
- Sponsor
- Weprom
COVID, Drug Effect
New Antiviral Drugs for Treatment of COVID-19
Background: In December 2019, SARS-CoV-2 was isolated on Vero E6 and Huh7 cell lines after an outbreak of pneumonia of unknown origin in Wuhan, Hubei Province, China.
- Trial name
- NCT04392427
- Testing
- Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days :
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Mansoura University
Covid19, SARS (Severe Acute Respiratory Syndrome)
Proxalutamide Treatment for COVID-19 Patients in Intensive Care Unit
The purpose of this study is to assess the efficacy and safety of Proxalutamide as a treatment for COVID-19 patients in the intensive care unit
- Trial name
- NCT04853927
- Testing
- Proxalutamide
- Where
- Brazil
- Sponsor
- Applied Biology, Inc.
Acute Respiratory Failure, Covid19
Proportional Open Ventilation (POV) Device and Its Efficacy in Managing Acute Respiratory Failure in COVID-19 Patients
To evaluate the use of Life2000® Ventilator, a novel proportional open ventilation system in critical care use of acute onset of respiratory failure (ARF) and mild to moderate forms of acute respiratory distress syndrome (ARDS)…
- Trial name
- NCT04581161
- Testing
- Life2000® Ventilator
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Hill-Rom
Covid19
Electrocardiographic QRS Axis Shift ,Rotation and COVİD-19
In patients with coronavirus disease (COVID-19), severe dyspnea is the most dramatic complication.Severe respiratory difficulties may include electrocardiographic frontal QRS axis rightward shift (Rws) and clockwise rotation…
- Trial name
- NCT04698083
- Testing
- Electrocardiography ,Tomographic imaging
- Where
- Turkey (Türkiye)
- Volunteers
- 160 people
- Sponsor
- Ankara Education and Research Hospital
Covid19
TOcilizumab and Covid-19 : Risk of Severe INfection
SARS-CoV2 is responsible for a pandemic that has been evolving for approximately 18 months. The virus' capacity for dissemination and its virulence are responsible for significant morbidity and mortality.
- Trial name
- TOCSIN (NCT05017441)
- Where
- France
- Volunteers
- 1,200 people
- Sponsor
- Fondation Hôpital Saint-Joseph
COVID-19
Immune Response of Asymptomatic EHPAD Employees Infected With COVID-19
The investigators performed in April 2020, a screening campaign of asymptomatic staff working in elderly nursing homes in Paris France (EHPAD), where the virus had been circulating actively in March and April 2020.
- Trial name
- SERASYMPTO (NCT05128656)
- Testing
- serology
- Where
- France
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Sars-CoV2
COVID-19 Respiratory Distress and Antithrombotic Drugs in Subject's Habits
Current management of VID-19 consists of oxygen support without specific treatment. Hospitalization may suddenly require delayed resuscitation.
- Trial name
- CRASH (NCT04412473)
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- University Hospital, Strasbourg, France
Covid19
Post Covid Syndrome: Clinical Pattern and Functional Assessment
Aim(s) of the Research : 1. Identify post covid symptoms 2. prevalance of post covid syndrome among survivours
- Trial name
- NCT04561141
- Volunteers
- 85 people
- Sponsor
- Assiut University
Coronavirus
Clinical Characteristics and Prognostic Factors of Patients With COVID-19
As of February 17th, 2020, China has 70635 confirmed cases of coronavirus disease 2019 (COVID-19), including 1772 deaths. Human-to-human spread of virus via respiratory droplets is currently considered to be the main route of…
- Trial name
- NCT04328454
- Testing
- retrospective analysis
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shanghai 10th People's Hospital
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.